H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress
HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target
I-MAB Analyst Ratings
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
I-MAB Analyst Ratings
HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target
I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline
Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.
I-MAB Analyst Ratings
Needham Reiterates Buy on I-MAB, Maintains $6 Price Target
I-MAB Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
I-MAB Analyst Ratings
Needham Maintains Buy on I-MAB, Lowers Price Target to $6
I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline
I-MAB Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)
Needham Maintains Buy on I-MAB, Lowers Price Target to $23
No Data
No Data